Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma

• Verfasst von: Russell, Nigel [VerfasserIn]
• Verfasst von: Douglas, Kenny [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Mohty, Mohamad [VerfasserIn]
• Verfasst von: Carlson, Kristina [VerfasserIn]
• Verfasst von: Ossenkoppele, G. J. [VerfasserIn]
• Verfasst von: Milone, Giuseppe [VerfasserIn]
• Verfasst von: Pareja, Macarena Ortiz [VerfasserIn]
• Verfasst von: Shaheen, Daniel [VerfasserIn]
• Verfasst von: Willemsen, Arnold [VerfasserIn]
• Verfasst von: Whitaker, Nicky [VerfasserIn]
• Verfasst von: Chabannon, Christian [VerfasserIn]
• Titel: Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma
• Titelzusatz: results of the prospective PREDICT trial
• Verf.angabe: Nigel Russell, Kenny Douglas, Anthony D. Ho, Mohamad Mohty, Kristina Carlson, G.J. Ossenkoppele, Giuseppe Milone, Macarena Ortiz Pareja, Daniel Shaheen, Arnold Willemsen, Nicky Whitaker, and Christian Chabannon
• E-Jahr: 2013
• Jahr: 2013-02-01
• Umfang: 7 S.
• Fussnoten: Gesehen am 24.01.2022
• Titel Quelle: Enthalten in: Haematologica, the hematology journal
• Ort Quelle: Pavia : Ferrata Storti Foundation, 2005
• Jahr Quelle: 2013
• Band/Heft Quelle: 98(2013), 2 vom: Feb., Seite 172-178
• ISSN Quelle: 1592-8721
• DOI: doi:10.3324/haematol.2012.071456
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1787000001

Abstract

In Europe, the combination of plerixafor + granulocyte colony-stimulating factor is approved for the mobilization of hematopoietic stem cells for autologous transplantation in patients with lymphoma and myeloma whose cells mobilize poorly. The purpose of this study was to further assess the safety and efficacy of plerixafor + granulocyte colony-stimulating factor for front-line mobilization in European patients with lymphoma or myeloma. In this multicenter, open label, single-arm study, patients received granulocyte colony-stimulating factor (10 μg/kg/day) subcutaneously for 4 days; on the evening of day 4 they were given plerixafor (0.24 mg/kg) subcutaneously. Patients underwent apheresis on day 5 after a morning dose of granulocyte colony-stimulating factor. The primary study objective was to confirm the safety of mobilization with plerixafor. Secondary objectives included assessment of efficacy (apheresis yield, time to engraftment). The combination of plerixafor + granulocyte colony-stimulating factor was used to mobilize hematopoietic stem cells in 118 patients (90 with myeloma, 25 with non-Hodgkin's lymphoma, 3 with Hodgkin's disease). Treatment-emergent plerixafor-related adverse events were reported in 24 patients. Most adverse events occurred within 1 hour after injection, were grade 1 or 2 in severity and included gastrointestinal disorders or injection-site reactions. The minimum cell yield (≥2×106 CD34+ cells/kg) was harvested in 98% of patients with myeloma and in 80% of those with non-Hodgkin's lymphoma in a median of one apheresis. The optimum cell dose (≥5×106 CD34+ cells/kg for non-Hodgkin's lymphoma or ≥6×106 CD34+ cells/kg for myeloma) was harvested in 89% of myeloma patients and 48% of non-Hodgkin's lymphoma patients. In this prospective, multicenter European study, mobilization with plerixafor + granulocyte colony-stimulating factor allowed the majority of patients with myeloma or non-Hodgkin's lymphoma to undergo transplantation with minimal toxicity, providing further data supporting the safety and efficacy of plerixafor + granulocyte colony-stimulating factor for front-line mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma or myeloma.